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Abstract
Background: The worldwide appearance of drug-resistant strains of H. pylori motivates a search
for new agents with therapeutic potential against this family of bacteria that colonizes the stomach,
and is associated with adenocarcinoma development. This study was designed to assess in vitro the
anti-H. pylori potential of cathelicidin LL-37 peptide, which is naturally present in gastric juice, its
optimized synthetic analog WLBU2, and the non-peptide antibacterial agent ceragenin CSA-13.
Results:  In agreement with previous studies, increased expression of hCAP-18/LL-37 was
observed in gastric mucosa obtained from H. pylori infected subjects. MBC (minimum bactericidal
concentration) values determined in nutrient-containing media range from 100-800 μg/ml for LL-
37, 17.8-142 μg/ml for WLBU2 and 0.275-8.9 μg/ml for ceragenin CSA-13. These data indicate
substantial, but widely differing antibacterial activities against clinical isolates of H. pylori. After
incubation in simulated gastric juice (low pH with presence of pepsin) CSA-13, but not LL-37 or
WLBU2, retained antibacterial activity. Compared to LL-37 and WLBU2 peptides, CSA-13 activity
was also more resistant to inhibition by isolated host gastric mucins.
Conclusion: These data indicate that cholic acid-based antimicrobial agents such as CSA-13 resist
proteolytic degradation and inhibition by mucin and have potential for treatment of H. pylori
infections, including those caused by the clarithromycin and/or metronidazole-resistant strains.
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Background
Helicobacter pylori is carried by more than half of the
world's adult population [1]. It can chronically colonize
the human gastric mucosa, where it is found in the mucus
layer and is adhered to epithelial cells [2]. Although most
infected subjects remain asymptomatic, infection with H.
pylori can promote severe gastritis [3] and significantly
increase the risk of gastric malignancies [4,5]. In some epi-
demiological studies, H. pylori eradication was shown to
be effective in gastric cancer prevention [6,7]. Addition-
ally, H. pylori eradication was found to decrease the inci-
dence and the severity of lesions with carcinogenic
potential in animal models [8,9]. Natural mechanisms
that protect the host from H. pylori infections depend on
the function of the innate defense system in which anti-
bacterial peptides such as cathelicidin LL-37 [10,11] and
O-glycans in gastric mucin [12] play a key role.
LL-37 is a proteolytically processed peptide derived from
the C-terminal domain of human cathelicidin (hCAP-18/
LL-37) that is constitutively released to the extracellular
space by phagocytic granulocytes and epithelial cells [13].
Functions ascribed to LL-37 include prevention of bacte-
rial growth [14], neutralization of bacterial wall molecule
bioactivity [15], and activation of host cells by binding
specific cell membrane receptors [16-18]. H. pylori upreg-
ulates the production of LL-37/hCAP18 by the gastric epi-
thelium, suggesting that cathelicidin or its derivative LL-
37 contributes to determining the balance between host
mucosal defense and H. pylori survival mechanisms that
govern chronic infection with this gastric pathogen
[10,11].
Cationic antibacterial peptides (CAPs) including LL-37
have been extensively investigated as a potential source of
new antibacterial molecules. The engineered WLBU2 pep-
tide whose residues are arranged to form an amphipathic
helical structure with optimal charge and hydrophobic
density, overcomes some limitations of natural LL-37
such as sensitivity to Mg2+ or Ca2+ and inactivation by
blood serum [19]. Therefore WLBU2 could treat infec-
tions where LL-37 is ineffective. In order to generate mol-
ecules able to mimic CAPs' ability to compromise
bacterial membrane integrity, non-peptide ceragenins
with cationic, facially amphiphilic structures characteristic
of most antimicrobial peptides were developed. Cera-
genins such as CSA-13 reproduce the required CAP mor-
phology using a bile-acid scaffolding and appended
amine groups [20]. They are bactericidal against both
Gram-positive and Gram-negative organisms, including
drug-resistant bacteria such as clinically relevant methicil-
lin-resistant Staphylococcus aureus (MRSA), and a previous
susceptibility study demonstrated that CSA-13 has a
MIC50/MBC50 ratio of 1 [21,22]. In this study we compare
the bactericidal potency of LL-37, WLBU2 and CSA-13
against clinical isolates of H. pylori. The results suggest that
cholic acid-based mimics of antimicrobial peptide such as
CSA-13 have potential for treatment of H. pylori infection,
including those caused by the clarithromycin and/or met-
ronidazole-resistant strains.
Results
Immunohistochemical probing of human gastric mucosa 
sections with anti-hCAP-18/LL-37 antibody
Microscopic images of mucosal biopsies after immuno-
histochemical evaluation with anti-hCAP-18/LL-37 anti-
body are shown in Figure 1. The DAB-positive staining
indicates the presence of the LL-37 peptide and/or its par-
ent protein hCAP-18. High intensity DAB staining (indi-
cated by brown color) at the mucus-producing epithelial
cells and fundic glands indicates high accumulation of
hCAP-18/LL-37 peptide most likely driven by LL-37 spe-
cific interaction with mucin, which was reported in previ-
ous studies [23,24]. The distribution of hCAP-18/LL-37 in
the more differentiated epithelial cell population of the
gastric mucosa differs from that found for human β-
defensin 2 [10] or lysozyme [25] but is similar to that
observed in the colon [26]. Gastric mucosal biopsies from
patients infected with H. pylori show higher intensity of
DAB staining compared to those obtained from non-
infected subjects. According to previous reports, this result
indicates a host defense response to H. pylori [11], which
is partly based on increased expression of hCAP-18/LL-37
by gastric epithelial cells.
Bactericidal activity of LL-37, WLBU-2 peptides and 
ceragenin CSA-13 against different strains of H. pylori
To identify resistant strains, clinical isolates of H. pylori
were subjected to MIC evaluation (Table 1) with several
antibiotics currently used in clinical treatment of H. pylori
infection. Among seven tested isolates obtained from dif-
ferent subjects, strain 4 was resistant to metronidazole
and strains 5, 6, 7 were resistant to both metronidazole
and clarithromycin. All isolates were susceptible to amox-
icillin and tetracycline. Consistent with previous reports
on the effects of hBD-1, h-BD-2 and LL-37 peptides
against H. pylori [10,11] all isolated strains of H. pylori
were killed after 6 hours incubation with LL-37, WLBU2
and CSA-13 with average MBC (μg/ml) values 8.9 ± 4.03;
5.23 ± 2.7 and 0.31 ± 0.25 when MBC was evaluated in
HEPES buffer, or 300 ± 232, 53 ± 41 and 2.98 ± 3.11 when
MBC was evaluated in Brucella Broth Bullion respectively
(Figure 2). Evaluation of MBC values in HEPES buffer
with addition of 2 mM MgCl2 for H. pylori ATCC 43504
revealed an eight fold increase for LL-37, and a four fold
increase for both WLBU2 and CSA-13 (data not show).
Antibacterial activity of LL-37, WLBU2 and CSA-13 after 
pre-incubation at low pH with pepsin or mucin
In addition to known inhibition of CAPs antibacterial
activity by divalent cations such as Mg2+ and Ca2+, the pro-
teolytic activity of pepsin may also compromise CAPsBMC Microbiology 2009, 9:187 http://www.biomedcentral.com/1471-2180/9/187
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function in the gastric juice environment with the pres-
ence of mucins, and low pH. To address this possibility we
evaluated the antibacterial activity against Escherichia coli
MG1655 after 3 hours pre-incubation of LL-37, WLBU2
and CSA-13 in simulated gastric juice in comparison to
activity after their pre-incubation in PBS at pH 7.4. Before
conducting the killing assay, the pH of samples with low
pH and low pH/pepsin was adjusted to 7.4. The antibac-
terial activity of LL-37 and WLBU2 peptides against E. coli
MG1655 was not significantly changed after pre-incuba-
tion at pH ~1.5, but was lost after pre-incubation at pH
~1.5 in the presence of pepsin (Figure 3A and 3B). In con-
trast, the antibacterial activity of CSA-13 was unchanged
by pre-incubation at pH ~1.5 with or without pepsin (Fig-
ure 3C). On the other hand, bactericidal activities of all
components were compromised to various extents when
tested using a bacterial killing assay in the presence of
purified gastric mucin. In close agreement with results
obtained from this E. coli MG1655 study, MBC values of
LL-37 peptide evaluated after 1H pre-incubation with
buffer at low pH containing pepsin or mucin was
increased but those of CSA-13 were nearly unchanged
(Figure 3D). All evaluated agents lost antibacterial activity
in PBS supplemented with 10% human bile (a concentra-
tion that does not interfere with E. coli MG1655 growth -
data not shown). This result suggests that physico-chemi-
cal properties of antibacterial molecules promote their
insertion in bile lipoprotein, thereby limiting their inter-
action with the bacterial wall. There has been no study to
evaluate antibacterial activity of CAPs in duodenal juice,
but these results indicate that bile reflux into the stomach
may interfere with CAPs activity.
Presence of hCAP-18/LL-37 peptide in mucosal biopsies from the human stomach detected using immunohistochemical analy- sis with monoclonal antibodies to human CAP-18/LL-37 Figure 1
Presence of hCAP-18/LL-37 peptide in mucosal biopsies from the human stomach detected using immunohis-
tochemical analysis with monoclonal antibodies to human CAP-18/LL-37. Samples A/B and C/D represent the spec-
imens obtained from non-infected and H. pylori infected subjects respectively. Data shown are representative of five 
experiments.
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Analytical characterization of LL-37 and CSA-13 after 
incubation with pepsin
Mass spectrometry analysis (Figure 4) reveals that three
hours incubation with pepsin results in extensive degrada-
tion of LL-37. However, at low pH, pepsin digestion is
highly specific and LL-37 peptide cleavage is limited to the
site with hydrophobic amino acids. Potential cleavage
sites predicted by PeptideCutter characterization software
http://kr.expasy.org/tools/peptidecutter/, suggest that LL-
37 digestion with pepsin in our experimental conditions
should release 11 products, including 3 shorter peptides
(RKSKEKIGKE, FKRIVQRIKD and LVPRTES). These pre-
dictions are consistent with mass spectral analysis, which
does not show the presence of any intact LL-37 remaining
following incubation with pepsin at low pH, but does
reveal the emergence of multiple new peaks with different
retention times. The remaining antibacterial activity of LL-
37 following treatment with pepsin (Figure 3A and 3D) in
the killing assays likely represents the residual activity of
these LL-37 fragments. Contrary to the observed degrada-
tion of LL-37, CSA-13 analytical characterization was not
changed after incubation with pepsin at low pH.
Toxicity of LL-37, WLBU2 and CSA-13 against RBC and 
human adenocarcinoma cells
Non-specific insertion of antibacterial peptides and their
mimics into host cell membranes can cause toxicity. Host
cell membrane permeabilization can be measured by the
release of proteins such as hemoglobin and LDH from the
cytosol to the extracellular space. By evaluating hemo-
globin and LDH release (Figure 5A and 5B), we show no
significant membrane permeabilization by any tested
molecules in the range at which they have bactericidal
activity in saline buffers (Figure 2A, Figure 3). This finding
was confirmed by microscopic evaluation of adenocarci-
noma cell morphology showing no visible difference
between the control cells and those treated with 10 μg/ml
LL-37, WLBU2 or CSA-13 (Figure 5C). However an
increase in hemoglobin and LDH release was observed
with increasing concentration. Among the three mole-
cules tested, WLBU2 was the strongest hemolytic agent,
but all of them showed similar ability to compromise ade-
nocarcinoma cell membrane integrity (Figure 5B and 5C).
CSA-13 bactericidal concentrations against H. pylori and
E. coli MG1655 (Figures 2A, 2B and 3C) evaluated in
saline as well as nutrient containing buffer were below its
minimal hemolytic concentration and below concentra-
tions causing dysfunction of adenocarcinoma cell mem-
branes.
Bactericidal activity against H. pylori Figure 2
Bactericidal activity against H. pylori. Minimum bacteri-
cidal concentration (MBC) of LL-37 (white column), WLBU2 
(gray column) and CSA-13 (black column) against H. pylori 
(ATCC 43504 strain and seven clinical isolates obtained from 
mucosal samples from different subjects) evaluated in HEPES 
(panel A) or Brucella Broth Bulion (panel B). MBC indicates 
concentrations at which compounds completely eradicate an 
inoculum of H. pylori.
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Table 1: Evaluation of sensitivity of clinical strains of H. pylori to 
antibiotics. 
H. pylori strains Antibiotics
AMX CLR TET Metronidazole
ATCC 43504 0.016 0.094 0.25 64.0 ®
1 0.094 0.125 0.75 0.19
2 <0.016 0.19 0.125 0.094
3 0.016 0.25 3.0 0.5
4 0.032 0.047 2.0 32.0 ®
5 0.25 64.0 ® 1.0 96.0 ®
6 0.032 1.5 ® 1.5 32.0 ®
7 0.047 1.5 ® 2.0 48.0 ®
MIC values (μg/ml) (AMX-amoxicillin, CLR-clarithromycin, TET-
tetracycline)BMC Microbiology 2009, 9:187 http://www.biomedcentral.com/1471-2180/9/187
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Discussion
The rate of successful treatment of H. pylori stomach infec-
tion, achieved with combination therapies of two antibi-
otics and a proton pump inhibitor has declined from over
90% to about 80% during the past decade [27]. In addi-
tion, the cost of this therapy is significant, and therefore a
need for more widely available means of treating or pre-
venting H. pylori infection still exists [28]. New agents to
treat H. pylori infections are necessary also due to increas-
ing drug-resistance problems caused by extensive use of
antibiotics [29] and the adaptive survival mechanisms of
pathogenic bacteria to counteract currently used antimi-
crobials. For example, H. pylori strains resistant to amoxi-
cillin, metronidazole and clarithromycin have been
Antibacterial activity against E. coli MG1655 and H. pylori strain ATCC 43504 Figure 3
Antibacterial activity against E. coli MG1655 and H. pylori strain ATCC 43504. Antibacterial activity of LL-37 (panel 
A), WLBU2 (panel B) and CSA-13 (panel C) against E. coli MG1655 after pre-incubation (3 h at 37°C) in PBS (open circles), 
simulated gastric juice at pH ~1.5 (squares), simulated gastric juice with pepsin (diamonds), simulated gastric juice with mucin 
(triangles) and PBS with human bile (10%) obtained from the gallbladder (filled circle). Data shown are means ± SD of three to 
four experiments. MBC of LL-37 (white column) and CSA-13 (black column) (panel D) against H. pylori (ATCC 43504) after 
pre-incubation (1 h at 37°C) in simulated gastric juice at pH ~1.5 (A), simulated gastric juice with pepsin (B) and in presence of 
mucin (C)
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Mass spectrometry analysis Figure 4
Mass spectrometry analysis. Mass spectrometry analysis of LL-37 (panel A) and CSA-13 (panel B) in PBS (curve 1) low pH 
buffer (curve 2) and low pH buffer with presence of pepsin (curve 3). The total ion chromatogram (TIC) is presented for each 
sample condition with an inset mass-to-charge (m/z) spectra showing intensity for the boxed TIC peaks. The molecular weight 
of intact LL-37 is 4494, which can be observed with multiple charges (m/z = 4 MW = 1124, m/z = 5 MW = 900, etc) in positive 
ion mode. The molecular weight of CSA13 is 678, which can be observed directly and with multiple charges. Data from one 
experiment are shown.BMC Microbiology 2009, 9:187 http://www.biomedcentral.com/1471-2180/9/187
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reported [30,31]. Methods to improve treatments for H.
pylori might be guided by insight into the natural mecha-
nisms by which infected patients respond to this bacte-
rium and the reasons why the normal host-defense
mechanisms fail.
This study confirms a previous report of increased hCAP-
18/LL-37 expression in gastric mucosa of subjects infected
with H. pylori [11]. This finding suggests that increasing
production of the bactericidal peptide LL-37 may play a
key role in host defense against H. pylori [11]. However,
this bactericidal response in some subjects is insufficient
and H. pylori infection can still reach a chronic stage. The
lack of bactericidal function of LL-37 in this setting has
suggested that increased expression of hCAP-18/LL-37
peptide in gastric mucus of infected subjects may have
additional functions as an anti-inflammatory and growth
stimulating agent. Indeed, it was recently shown that gas-
tric ulcer healing in rats is promoted by cathelicidin-medi-
ated transactivation of epidermal growth factor receptors
(EGFR) via the transforming growth factor alpha (TGFα)
signaling pathway [32]. Alternatively, loss of defense
against H. pylori may be due to loss of antibacterial func-
tion of LL-37 in the milieu of the gastric mucosa. Conse-
quently, design of antimicrobial agents that are more
effective in this setting can be beneficial.
Motivated by immunohistological results, the activity of
LL-37 against clinical isolates of H. pylori and  E. coli
MG1655 under biologically relevant conditions was com-
pared with that of the synthetic peptide WLBU2 and the
ceragenin CSA-13. This study shows that CSA-13, contrary
to LL-37 and WLBU2 peptides, maintains strong bacteri-
cidal activity in the presence of mucin and after preincu-
bation with pepsin at low pH. These conditions represent
unique challenges related to H. pylori treatment, as these
bacteria in the stomach are protected from the acidic envi-
ronment by a thick mucus layer and the effectiveness of
many antimicrobial drugs is greatly diminished at acidic
pH [31]. Accordingly, the first effective therapy for H.
pylori infection was a combination of relatively pH-insen-
sitive antimicrobial drugs such as bismuth, tetracycline
and metronidazole [33]. In addition, as the stomach peri-
odically empties its contents (topical therapy tends to be
diluted and washed out) the finding that CSA-13 has bac-
tericidal activity at much lower concentration then LL-37,
after the same incubation time (3-6 hours) [11], suggests
that CSA-13 may have therapeutic potential for treatment
of H. pylori infection. The antibacterial activity of CSA-13,
which has a smaller net charge and a unique distribution
of this charge over a steroid scaffold when compared with
LL-37 and WLBU2 peptides, was also found to be less
inhibited by mucin isolated from gastric mucosa. Thera-
Evaluation of cell toxicity Figure 5
Evaluation of cell toxicity. Hemoglobin and LDH release 
from human red blood cells and human gastric adenocarci-
noma cells (panel A and B respectively) after addition of LL-
37 (circles), WLBU2 (diamonds), and CSA-13 (triangles), fol-
lowed by incubation for 1 h at 37°C. Data shown are means 
± SD of three experiments. Morphology of human gastric 
adenocarcinoma cells before (control) and after LL-37, 
WLBU2 and CSA-13 treatment was evaluated by phase-con-
trast microscopy (panel C). Data from one representative 
experiment are shown. Two other experiments revealed 
similar results.
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peutic potential based on the ability of CSA-13 to eradi-
cate H. pylori is also supported by previously reported
antibacterial activity against other bacteria strains, includ-
ing clinical isolates of Pseudomonas aeruginosa [21] and S.
aureus [22]. CSA-13's unique ability to compromise bacte-
rial membrane integrity and the chemical nature of this
low-molecular-mass compound that translates to lower
cost of synthesis compared to cationic antibacterial pep-
tides suggest that CSA-13 or perhaps other ceragenins
have potential for treatment of H. pylori infection, includ-
ing those caused by its resistant strains.
Conclusion
Bactericidal activity of ceragenin CSA-13 is maintained
after preincubation in simulated gastric juice and in the
presence of mucin. This in vitro evaluation indicates a sig-
nificant potential of this molecule in treatment of stom-
ach mucosal infection.
Methods
Antibacterial agents
LL-37 (NH2-LLGDFFRKSKEKIGKEFKRIVQRIKDFLRN-
LVPRTES-COOH) and WLBU2 (NH2-RRWVRRVRRWVR-
RVVRVVRRWVRR-COOH) peptides were purchased from
Bachem (King of Prussia, PA). CSA-13 was prepared as
previously described [34]. Amoxicillin (AMX), clarithro-
mycin (CLR), tetracycline (TET) and metronidazole were
purchased from Sigma.
Collection of gastric mucosal and bile samples
During gastroscopy, performed with either a GIF V2 or
Q145 (Olympus) gastroscope, several gastric mucosal
slices were taken from the prepyloric and corpus regions
of the stomach. H. pylori infection was established in the
biopsy specimens using a urease test (CLO-test). Human
bile was obtained from the gallbladder of patients under-
going cholecystectomy. Samples were filter-sterilized
through a 0.45 μm membrane before being diluted in PBS
(1:1) and mixed with antibacterial agents used in bacteria
killing assays. The studies were approved by Medical Uni-
versity of Bialystok Ethics Committee for Research on
Humans and Animals, and all patients gave informed
written consent for participation in the study.
Immunohistochemical studies
Immunohistochemical studies were performed on forma-
lin-fixed, paraffin-embedded human gastric mucosal sec-
tions using a rabbit anti-LL-37 antibody (H-075-06, used
at 1:100 dilution; Phoenix Pharamceuticals Inc.). Paraf-
fin-embedded materials were sectioned to 5 μm thickness
and floated on distilled water at 45°C. Sections were then
mounted on slides and placed in 57°C oven overnight.
The sections were deparaffinized according to standard
procedures and quenched with 0.9% hydrogen peroxide
in methanol for 30 minutes. The sections were incubated
with primary antibody at 37°C for 60 minutes, washed
with 1% PBSA (1% BSA in PBS), and subjected to binding
with secondary antibody (biotinylated goat anti-Rabbit
IgG, 1:400 dilution). Amplification was performed with a
Vectastain ABC kit, and an HRP detection system was used
to colocalize peroxidase activity with a DAB substrate. The
sections were counterstained with hematoxylin. Samples
were viewed with a Nikon Eclipse 80 microscope under
40× magnification.
Evaluation of MIC and MBC
The minimal inhibitory concentration (MIC) of conven-
tional antibiotics against seven different clinical isolates
of  H. pylori (9 × 108  CFU/ml) was determined using
Muller-Hinton agar (MH) containing 5% sheep blood.
The incubation was continued for 4 days at 35°C in
microaerophilic conditions maintained with use of a Gas
Pack-Campylobacter gas generating kit BR60. Clinical iso-
lates of H. pylori were considered resistant to respective
antibiotics when the MIC values were above 4 μg/ml for
AMX, 1 μg/ml for CLR and 16 μg/ml for TET and Metron-
idazole. The minimal bactericidal concentration (MBC)
of antibacterial agents was evaluated using an inoculum at
108 CFU/ml. After a 6-hour incubation at 37°C, 10 μl aliq-
uots of the suspensions were spotted on Columbia agar
supplemented with sheep blood (5%).
Bacteria killing assay
The bactericidal activities of LL-37, WLBU2 peptides and
ceragenin CSA-13 against E. coli MG1655 in the presence
of mucin or pepsin from porcine mucus (Sigma) and
human bile were measured as previously described [35].
Bacteria were grown to mid-log phase at 37°C (controlled
by the evaluation of optical density at 600 nm) and resus-
pended in PBS buffer (pH = 7.4). The bacteria suspensions
were then diluted 10 times in 100 μl of solutions contain-
ing antibacterial agents by themselves or with mucin
(1000 μg/ml), or bile (the final 1:10 bile dilution mimics
the environment of the upper small intestine into which
bile is secreted [36] (pH = 7.4)). In another set of experi-
ments antibacterial activity of these components was
determined following their preincubation in simulated
gastric juice [36,37] at pH ~1.5 with and without pepsin
(0.5 mg/ml). After incubating bacteria with antibacterial
molecules for one-hour at 37°C, the bacterial suspensions
were placed on ice and diluted 10- to 1000- fold. Aliquots
of each dilution (10 μl) were spotted on LB Agar plates for
overnight culture at 37°C. The number of colonies at each
dilution was counted the following morning. The colony
forming units (CFU/ml) of the individual samples were
determined from the dilution factor.
Mass spectrometry
Analytical characterization was performed on the CSA-13
and LL-37 suspensions after 3H incubation with pepsin
(0.5 mg/ml) at low pH (~1,5) at 37°C, using the Shi-
madzu (Columbia, MD) instrument (the LC-MS systemBMC Microbiology 2009, 9:187 http://www.biomedcentral.com/1471-2180/9/187
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consisted of a LC-20AB solvent delivery system and SIL-
20A auto-sampler coupled to dual wavelength UV-Vis
detector and a LCMS 2010EV single quadrupole mass
spectrometer), coupled to a Shimadzu Premier C18 col-
umn (150 mm × 4.6 mm i.d., 5 μm particle size). The
mobile phase flow rate was 1 ml/min with a starting ratio
of 90% mobile phase A (water) and 10% mobile phase B
(acetonitrile) both with 0.1% (v/v) formic acid. The ana-
lytical method consisted of the following steps: (i) sample
injection and holding at 10% B for 5 min, (ii) linear gra-
dient from 10% to 90% B over 15 minutes, (iii) holding
at 90% B for 5 minutes, (iv) isocratic step to 10% B and
holding for 5 minutes prior to the next sample injection.
Mass spectrometry was performed on the eluent using
electrospray ionization (ESI) in positive ion mode with a
scanned m/z range from 160-2000.
Red blood cell lysis
The hemolytic activity of LL-37, WLBU-2 and CSA-13 (0-
200 μg/ml), against human red blood cells (RBC) was
tested using erythrocytes suspended in PBS. RBC prepared
from fresh blood (Hematocrit ~5%) were incubated for 1
h at 37°C after addition of test molecules. Relative hemo-
globin concentration in supernatants after centrifugation
at 2000 × g was monitored by measuring the absorbance
at 540 nm. 100% hemolysis was taken from samples in
which 2% Triton X-100 was added.
Cell culture
Human gastric adenocarcinoma cells (ATCC; CRL-1739)
were maintained in DMEM (BioWhittaker) culture sup-
plemented with 10% heat-inactivated fetal bovine serum
(Hyclone) at 37°C and 5% CO2. For LDH release assay
and microscope evaluation cells were plated in 24 well
plates and grown to confluence. In all experiments, the
medium was changed to serum-free media ~12 h prior to
cell treatment with LL-37, WLBU2 and CSA-13 (0-200 μg/
ml) in individual wells, for 1 hour. Cell culture medium
was then collected, centrifuged (10 mins, 5000 rpm, RT)
and subjected to LDH evaluation (LDH-cytotoxicity Assay
Kit; BioVision Inc.)
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